Study · Randomized controlled trial · 2009

4 results

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B

Lancet (London, England)24 Sept 2008Cited by 798 (Europe PMC)

PMID18819705DOI10.1016/s0140-6736(08)61246-5PepBankPUB-18819705

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with early type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than glimepiride at 52 weeks.
In plain wordsIn adults with early type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than glimepiride.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at 52 weeks, 1.2 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c change
−0.84%
liraglutide 1.2 mg
HbA1c change
−0.51%
glimepiride
Difference
−0.33%
95% CI -0.53 to -0.13
Source sentences
Summary
At 52 weeks, HbA(1c) decreased by 0.51% (SD 1.20%) with glimepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014) and 1.14% (1.24%) with liraglutide 1.8 mg (-0.62; -0.83 to -0.42, p<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was change in proportion of glycosylated haemoglobin (HbA(1c)).
Summary · context
In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks.
Report a problemFND-1881970501
02HumanRandomized controlled trialEfficacy outcome
In adults with early type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than glimepiride at 52 weeks.
In plain wordsIn adults with early type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than glimepiride.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at 52 weeks, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c change
−1.14%
liraglutide 1.8 mg
HbA1c change
−0.51%
glimepiride
Difference
−0.62%
95% CI -0.83 to -0.42
Source sentences
Summary
At 52 weeks, HbA(1c) decreased by 0.51% (SD 1.20%) with glimepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014) and 1.14% (1.24%) with liraglutide 1.8 mg (-0.62; -0.83 to -0.42, p<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was change in proportion of glycosylated haemoglobin (HbA(1c)).
Summary · context
In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks.
Report a problemFND-1881970502
03HumanRandomized controlled trialSafety outcome
In adults with early type 2 diabetes, five patients on liraglutide 1.2 mg stopped treatment because of vomiting, and none did on glimepiride.
In plain wordsFive people on liraglutide 1.2 mg stopped treatment because of vomiting, and none on glimepiride did.
Peptide
Liraglutide
Outcome
IncreaseDiscontinuation due to vomiting, 1.2 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
Five patients in the liraglutide 1.2 mg, and one in 1.8 mg groups discontinued treatment because of vomiting, whereas none in the glimepiride group did so.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks.
Report a problemFND-1881970503
04HumanRandomized controlled trialSafety outcome
In adults with early type 2 diabetes, one patient on liraglutide 1.8 mg stopped treatment because of vomiting, and none did on glimepiride.
In plain wordsOne person on liraglutide 1.8 mg stopped treatment because of vomiting, and none on glimepiride did.
Peptide
Liraglutide
Outcome
IncreaseDiscontinuation due to vomiting, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
Five patients in the liraglutide 1.2 mg, and one in 1.8 mg groups discontinued treatment because of vomiting, whereas none in the glimepiride group did so.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks.
Report a problemFND-1881970504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 1 completed · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial page ClinicalTrials.govUpdated 5 May 2016

Status unknownNot applicableNCT02001363

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Chen Wei Ren, MDn = 90Nov 2013 to est. Mar 2016

Acute Myocardial Infarction

Trial page ClinicalTrials.govUpdated 5 Feb 2016

TerminatedPhase 3Results postedNCT00294723

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Novo Nordisk A/Sn = 746Feb 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.